Facing Heart Failure: Trends in the United States

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Facing Heart Failure: Trends in the United States

ReachMD Healthcare Image

Can we help reduce the risk of HFH and cardiovascular deaths in appropriate adult patients with symptomatic chronic HF and ejection fraction less than 45 percent? Tune in.


    VERQUVO® (vericiguat) is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.



    Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO® (vericiguat) to a pregnant female because it may cause fetal harm.  

    ● VERQUVO® (vericiguat) is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
    ● VERQUVO is contraindicated in pregnancy. 
    ● Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO® (vericiguat) may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.
    ● There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231 or at
    ● In a clinical trial, the most commonly observed adverse events with VERQUVO® (vericiguat) vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).
    ● Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.
    ● There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

    Before prescribing VERQUVO® (vericiguat), please read the accompanying Prescribing Information, including the Boxed Warning about embryo-fetal toxicity. The Medication Guide also is available.

  • Overview

    Join Dr. Norbert Moskovits, Practicing Cardiologist and Director of the Heart Failure Program at Maimonides Medical Center in New York, as he speaks about some of the challenges associated with heart failure and informs us of a treatment option for certain patients with chronic heart failure. 

Schedule11 Dec 2023